Clinical Trial

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Study acronym: Eluminate-4
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).
Trial Details
NCT Number NCT07662135
Lead Sponsor AstraZeneca
Conditions Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
Enrollment 900 participants
Start Date 2026-07-06
Primary Completion 2028-07-13 (estimated)
Study Completion 2028-07-13 (estimated)
Updated on ClinicalTrials.gov 2026-06-23